MyFinsight
Home
About
Contact
rare: the balance sheet
Income Statement
|
Cash Flow
|
Balance Sheet
For the quarter ending 2025-09-30, RARE has $1,190,445K in assets.
Balance Sheets Overview
00
No enough data to generate the overview
Subscribe for Financial Insights
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Quarterly
123
Balance Sheets
2025-09-30
2025-06-30
Total assets
1,190,445
1,306,265
Total liabilities, noncontrolling interest and stockholders' equity
1,190,445
1,306,265
Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Page 1
Subscribe for Financial Insights
Time Plot
Show the time plot by selecting a row from the table.
Balance Sheets
Prepaid expenses and
other assets
$53,215K
Inventory
$52,200K
Accounts receivable, net
$112,543K
Marketable debt securities
$222,738K
Cash and cash
equivalents
$202,510K
Other assets
$57,862K
Goodwill
$44,406K
Intangible assets, net
$172,943K
Marketable debt securities
$22,067K
Property, plant, and
equipment, net
$249,961K
Total current assets
$643,206K
Total assets
$1,190,445K
Total liabilities,
noncontrolling interest and...
$1,190,445K
Total stockholders
equity
$9,159K
Noncontrolling interest
$7,000K
Total liabilities
$1,174,286K
Accumulated deficit
-$4,403,288K
Treasury stock, at cost,
173,034 in 2025 and...
$7,991K
Accumulated other
comprehensive income (loss)
$820K
Additional paid-in capital
$4,411,531K
Other liabilities
$18,780K
Liabilities for sales of
future royalties
$763,735K
Deferred tax liabilities
$30,058K
Lease liabilities
$21,691K
Total current
liabilities
$340,022K
Deferred compensation
obligation
$7,991K
Common stock, par value
of 0.001 per share -...
$96K
Other liabilities
$1,236K
Liabilities for sales of
future royalties
$65,545K
Lease liabilities
$12,142K
Accrued liabilities
$220,526K
Accounts payable
$40,573K
Subscribe for Financial Insights
Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx Pharmaceutical Inc. (RARE)